Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMBRELLA B atezolizumab extension study
2023-506184-34-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 27
01
Overview
Phase 3, open-label trial of atezolizumab in cancer (2 arms), sponsored by Roche. Primary endpoint: Clinical benefit on atezolizumab-based or comparator therapy. Planned start Aug 2019; status: authorised.
02
Drugs
atezolizumab
03
Conditions
cancer
Beyond the preview
Go deeper on 2023-506184-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506184-34-00.